WuXi Biologics and Toregem BioPharma to advance tooth regeneration treatment
WuXi Biologics ("WuXi Bio"), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a strategic partnership with Toregem BioPharma, a biotech startup ... Read More
CANbridge Pharmaceuticals begins CAN103 phase 1/2 trial in Gaucher disease
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease ... Read More
WuXi vaccine manufacturing facility in Ireland gets $3bn contract
Chinese CDMO WuXi Vaccines has signed a 20-year contract worth around $3bn with an undisclosed vaccine company to use a dedicated vaccine manufacturing facility in ... Read More